SCHEDULE 13G/A: BlackRock Reports 4.9% Stake in LifeCore Biomedical
Beneficial Ownership Report
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 4.9% beneficial ownership in LifeCore Biomedical, Inc. common stock.
Summary
- BlackRock, Inc. reported beneficial ownership of 1,834,319 shares of LifeCore Biomedical, Inc. common stock.
- This ownership represents 4.9% of the total outstanding common stock of LifeCore Biomedical, Inc.
- BlackRock, Inc. holds sole voting power over 1,804,675 shares and sole dispositive power over 1,834,319 shares.
- The filing indicates that BlackRock, Inc. holds 5 percent or less of the class of securities.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- The filing is an Amendment No. 1 to a previous Schedule 13G statement.
Sentiment
Score: 5
Explanation: The filing is a factual report of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- BlackRock, Inc., a major institutional investor, maintains a significant stake in LifeCore Biomedical, Inc., which can be viewed as a vote of confidence.
- The filing confirms that BlackRock's ownership is for investment purposes in the ordinary course of business, not for control-related objectives.
Negatives
- The filing does not provide specific financial or operational details about LifeCore Biomedical, Inc. itself, limiting direct positive or negative assessment of the company's performance.
Risks
- The filing does not contain specific risks related to LifeCore Biomedical, Inc.'s operations or financial health; it is solely a beneficial ownership report.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding LifeCore Biomedical, Inc.'s future performance or BlackRock's future investment intentions beyond the current ownership disclosure.
Industry Context
This filing reflects a routine disclosure by a major asset manager, BlackRock, Inc., regarding its passive investment stake in a publicly traded company. Such disclosures are common for large institutional investors managing diverse portfolios across various industries, including the biomedical sector.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Authorized Signatories (BlackRock, Inc.) | Not specified, but previous Power of Attorney dated April 30, 2023 was revoked. | Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg and Brenda Schulz (acting severally). | 2025-01-21 | Update to the Power of Attorney for individuals authorized to execute ownership or control-person reporting requirements. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, designating new individuals to execute documents related to ownership or control-person reporting requirements. This new Power of Attorney revokes a previous one dated April 30, 2023. | 2025-01-21 | This is an internal governance update for BlackRock, Inc. to streamline its SEC filing processes, with no direct impact on LifeCore Biomedical, Inc.'s corporate governance. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming BlackRock's passive investment intent.
- Management: Offers insight into the composition of the company's shareholder base, with a major institutional holder.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. signatories. |
| 2025-09-30 | Date of event which required the filing of this statement. |
| 2025-10-17 | Date of signature for the Schedule 13G filing by BlackRock, Inc. |
Keywords
BlackRock, LifeCore Biomedical, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.